CN100435792C - 丁基苯酞类同系物在制备治疗抗血小板聚集和抗血栓药物中的应用 - Google Patents
丁基苯酞类同系物在制备治疗抗血小板聚集和抗血栓药物中的应用 Download PDFInfo
- Publication number
- CN100435792C CN100435792C CNB2004100366283A CN200410036628A CN100435792C CN 100435792 C CN100435792 C CN 100435792C CN B2004100366283 A CNB2004100366283 A CN B2004100366283A CN 200410036628 A CN200410036628 A CN 200410036628A CN 100435792 C CN100435792 C CN 100435792C
- Authority
- CN
- China
- Prior art keywords
- butylphthalide
- mii
- cerebral
- rat
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 206010008118 cerebral infarction Diseases 0.000 title abstract description 34
- 201000006474 Brain Ischemia Diseases 0.000 title abstract description 31
- 206010008120 Cerebral ischaemia Diseases 0.000 title abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 6
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 title abstract 6
- PWRAUQMRDXDCHM-UHFFFAOYSA-N 3-butyl-3-hydroxy-2-benzofuran-1-one Chemical compound C1=CC=C2C(CCCC)(O)OC(=O)C2=C1 PWRAUQMRDXDCHM-UHFFFAOYSA-N 0.000 claims description 17
- 239000003146 anticoagulant agent Substances 0.000 claims description 15
- 230000000702 anti-platelet effect Effects 0.000 claims description 7
- 230000002785 anti-thrombosis Effects 0.000 claims description 7
- 230000002776 aggregation Effects 0.000 claims description 6
- 238000004220 aggregation Methods 0.000 claims description 6
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 abstract description 70
- 229950005197 butylphthalide Drugs 0.000 abstract description 26
- 230000003405 preventing effect Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 230000004931 aggregating effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 48
- 230000000694 effects Effects 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 12
- 230000002490 cerebral effect Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000003727 cerebral blood flow Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 8
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 206010048962 Brain oedema Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 208000006752 brain edema Diseases 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000037149 energy metabolism Effects 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 210000001627 cerebral artery Anatomy 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000007971 neurological deficit Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001550 time effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000001387 apium graveolens Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000009811 bilateral tubal ligation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100366283A CN100435792C (zh) | 2004-04-23 | 2004-04-23 | 丁基苯酞类同系物在制备治疗抗血小板聚集和抗血栓药物中的应用 |
| PCT/CN2005/000556 WO2005102314A1 (fr) | 2004-04-23 | 2005-04-22 | Utilisation d'homologues de butylphthalide dans la preparation d'un medicament destine au traitement et a la prevention de l'ischemie cerebrale |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100366283A CN100435792C (zh) | 2004-04-23 | 2004-04-23 | 丁基苯酞类同系物在制备治疗抗血小板聚集和抗血栓药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1689563A CN1689563A (zh) | 2005-11-02 |
| CN100435792C true CN100435792C (zh) | 2008-11-26 |
Family
ID=35196721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100366283A Expired - Lifetime CN100435792C (zh) | 2004-04-23 | 2004-04-23 | 丁基苯酞类同系物在制备治疗抗血小板聚集和抗血栓药物中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN100435792C (fr) |
| WO (1) | WO2005102314A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101289438B (zh) * | 2007-04-16 | 2012-04-18 | 山东绿叶天然药物研究开发有限公司 | 3-(3'-羟基)-丁基苯酞酯及其制法和用途 |
| EP2332530B1 (fr) * | 2008-07-08 | 2014-10-08 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | Utilisation de 2-(hydroxypentyl) benzoate de potassium dans la fabrication de médicaments destinés à la prévention/au traitement de la démence sénile |
| KR20140073581A (ko) * | 2011-10-13 | 2014-06-16 | 쉬지아주앙 일링 파머서티컬 컴퍼니 리미트드 | 부틸프탈라이드 유도체 및 그의 제조방법 및 그의 용도 |
| CN102988349A (zh) * | 2012-11-19 | 2013-03-27 | 何晓涛 | Aphanamixoid A在制备抗血小板聚集药物中的应用 |
| CN104546828B (zh) * | 2013-10-09 | 2017-11-14 | 石药集团恩必普药业有限公司 | 丁基苯酞或其衍生物在制备治疗或预防糖尿病并发症的药物中的应用 |
| CN104546827B (zh) * | 2013-10-09 | 2019-12-27 | 石药集团恩必普药业有限公司 | 丁基苯酞或其衍生物在制备治疗或预防糖尿病的药物中的应用 |
| WO2016000265A1 (fr) * | 2014-07-04 | 2016-01-07 | 长弘生物科技股份有限公司 | Applications d'un composé phtalide |
| CN105267207A (zh) * | 2014-07-10 | 2016-01-27 | 米文君 | 一种药物组合物及其用途 |
| CN105348088A (zh) * | 2014-08-18 | 2016-02-24 | 米文君 | 一种新的化合物及其用途 |
| CN105523918A (zh) * | 2014-09-28 | 2016-04-27 | 米文君 | 一种新化合物及其用途 |
| CN105503584A (zh) * | 2014-09-28 | 2016-04-20 | 米文君 | 一种新的化合物及其用途 |
| WO2021185356A1 (fr) | 2020-03-20 | 2021-09-23 | 石药集团恩必普药业有限公司 | Utilisation de butylphtalide et dérivé associé |
| CN113666895B (zh) * | 2020-05-15 | 2023-12-08 | 华北制药集团新药研究开发有限责任公司 | 卤代2-苯并[c]呋喃酮类化合物及其应用 |
| CN112794831B (zh) * | 2021-04-06 | 2021-07-27 | 北京理工大学 | 3-(3′-羟基丁基)异苯并呋喃-1(3h)-酮衍生物及其组合物、制备方法和用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100097A (zh) * | 1993-09-09 | 1995-03-15 | 中国医学科学院药物研究所 | 芹菜甲素作为制备预防和治疗脑缺血引起的疾病的药物中的应用 |
| CN1257706A (zh) * | 1998-12-18 | 2000-06-28 | 中国医学科学院药物研究所 | 丁基苯酞在制备抗血栓形成及抗血小板聚集药物中的应用 |
-
2004
- 2004-04-23 CN CNB2004100366283A patent/CN100435792C/zh not_active Expired - Lifetime
-
2005
- 2005-04-22 WO PCT/CN2005/000556 patent/WO2005102314A1/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100097A (zh) * | 1993-09-09 | 1995-03-15 | 中国医学科学院药物研究所 | 芹菜甲素作为制备预防和治疗脑缺血引起的疾病的药物中的应用 |
| CN1257706A (zh) * | 1998-12-18 | 2000-06-28 | 中国医学科学院药物研究所 | 丁基苯酞在制备抗血栓形成及抗血小板聚集药物中的应用 |
Non-Patent Citations (6)
| Title |
|---|
| 3-（3`羟基丁基）异苯并呋喃-I（3H）-酮的合成. 王国新等.合成化学，第8卷第1期. 2000 |
| 3-(3`羟基丁基)异苯并呋喃-I(3H)-酮的合成. 王国新等.合成化学，第8卷第1期. 2000 * |
| 丁基苯酞对大鼠血栓形成及血小板功能的影响. 徐皓亮等.药学学报，第36卷第5期. 2001 |
| 丁基苯酞对大鼠血栓形成及血小板功能的影响. 徐皓亮等.药学学报，第36卷第5期. 2001 * |
| 丁基苯酞对局灶性脑缺血过程中线粒体损伤的保护作用. 熊杰等.药学学报，第35卷第6期. 2000 |
| 丁基苯酞对局灶性脑缺血过程中线粒体损伤的保护作用. 熊杰等.药学学报，第35卷第6期. 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1689563A (zh) | 2005-11-02 |
| WO2005102314A1 (fr) | 2005-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100435792C (zh) | 丁基苯酞类同系物在制备治疗抗血小板聚集和抗血栓药物中的应用 | |
| Fatehi et al. | A pharmacological study on Berberis vulgaris fruit extract | |
| CA2808520C (fr) | Methodes de traitement ou de prophylaxie de thrombose ou d'embolie | |
| CN107635404A (zh) | 用于治疗疾病的mct4抑制剂 | |
| WO2019128498A1 (fr) | Composition de gingko diterpène lactone | |
| CN111356469A (zh) | 包含虎杖根及桂心的用于抗血栓的组合物 | |
| CN101416995A (zh) | 一种淫羊藿提取物及制备方法、制剂和用途 | |
| CN112716950B (zh) | N-(2-苯基乙基)-5-苯基-吡啶-2-甲酰胺的新用途及其药物 | |
| CN108853501B (zh) | 磁感蛋白在改善神经退行性疾病中的应用 | |
| CN102030731A (zh) | 一种溶媒结晶法低温制备高纯度炎琥宁技术 | |
| CN103058975A (zh) | 从雪莲中提取5，7-二羟-4’-甲氧黄酮制剂在制备治疗缺血性脑卒中药物中的应用 | |
| CN101627992B (zh) | 左旋丁苯酞在制备治疗脑卒中药物中的应用 | |
| KR101788658B1 (ko) | 신규 히드록시 홍화황색소 a의 의약용 정제염 | |
| CN101474220A (zh) | 黄栌有效部位总黄酮的新用途及制剂 | |
| CN107496428A (zh) | 毛蕊异黄酮衍生物在制备促进内皮细胞增殖药物中的应用 | |
| CN113876818A (zh) | 预防脑卒中的复方灵芝孢子油提取物及其制备方法和应用 | |
| Pattanayak et al. | Evaluation of anti-inflammatory activity of Nyctanthes arbortristis leaves | |
| CN101297861A (zh) | 从槐花中提取的一种降糖活性物质 | |
| CN1647796A (zh) | 左旋丁苯酞在制备预防和治疗脑缺血疾病药物中的应用 | |
| CN102048824B (zh) | 一种用于治疗脑血管疾病的中药组合物及其应用 | |
| CN105434483B (zh) | 银杏酮酯组合物及其滴丸和应用 | |
| CN109248319A (zh) | 含有司坦类化合物和阿司匹林的药物组合物 | |
| CN112390846B (zh) | 一种抗肿瘤药物的晶型及其制备方法 | |
| CN101856468B (zh) | 一种治疗老年痴呆的药物组合物及其制备方法 | |
| CN107412668B (zh) | 一种药物组合物及其制备方法、制剂与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ENBIPU PHARMACY CO., LTD., SHIYAO GROUP. Effective date: 20130319 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 050051 SHIJIAZHUANG, HEBEI PROVINCE TO: 050035 SHIJIAZHUANG, HEBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130319 Address after: 050035 No. 226 the Yellow River Avenue, Shijiazhuang hi tech Development Zone, Hebei Patentee after: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd. Patentee after: SHIJIAZHUAN PHARMA GROUP NBP PHARMACEUTICAL Co.,Ltd. Address before: 050051 No. 276 West Zhongshan Road, Hebei, Shijiazhuang Patentee before: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20081126 |
|
| CX01 | Expiry of patent term |